Novanta Inc
NASDAQ:NOVT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novanta Inc
NASDAQ:NOVT
|
US |
|
Island Pharmaceuticals Ltd
ASX:ILA
|
AU |
|
A
|
Albireo Pharma Inc
F:BDQM
|
US |
|
Vytrus Biotech SA
MAD:VYT
|
ES |
|
Hakuyosha Co Ltd
TSE:9731
|
JP |
|
DCC PLC
LSE:DCC
|
IE |
Wall Street
Price Targets
NOVT Price Targets Summary
Novanta Inc
According to Wall Street analysts, the average 1-year price target for
NOVT
is 158.61 USD
with a low forecast of 139.38 USD and a high forecast of 178.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NOVT's stock price target?
Price Target
158.61
USD
According to Wall Street analysts, the average 1-year price target for
NOVT
is 158.61 USD
with a low forecast of 139.38 USD and a high forecast of 178.5 USD.
What is Novanta Inc's Revenue forecast?
Projected CAGR
8%
For the last 14 years the
compound annual growth rate for
Novanta Inc's revenue is
9%.
The projected
CAGR
for the next 2 years is
8%.
What is Novanta Inc's Operating Income forecast?
Projected CAGR
39%
For the last 14 years the
compound annual growth rate for
Novanta Inc's operating income is
8%.
The projected
CAGR
for the next 2 years is
39%.
What is Novanta Inc's Net Income forecast?
Projected CAGR
66%
For the last 14 years the
compound annual growth rate for
Novanta Inc's net income is
5%.
The projected
CAGR
for the next 2 years is
66%.
